Oral Terbinafine: Hepatic and Renal Effects
Oral terbinafine is primarily cleared by the kidneys and carries a rare but serious risk of hepatotoxicity; baseline liver function tests are mandatory before treatment, but routine periodic monitoring during therapy is not recommended unless patients develop symptoms of liver injury. 1, 2
Renal Effects and Considerations
Terbinafine is cleared mostly by the kidney (>70% of the administered dose is eliminated in urine), and clearance is decreased by approximately 50% in patients with severe renal impairment (creatinine clearance ≤50 mL/min) 1, 2. However, the drug has not been adequately studied in patients with significant renal dysfunction 2.
Key Renal Points:
- Use with caution in patients with creatinine clearance ≤50 mL/min due to reduced drug clearance
- No specific renal monitoring protocols are established in guidelines
- Dose adjustment recommendations are not well-defined due to limited data 2
Hepatic Effects and Toxicity
Terbinafine is associated with minimal hepatic toxicity in most patients, but rare cases of serious hepatotoxicity—including liver failure requiring transplantation or resulting in death—have been reported 1, 2.
Critical Hepatotoxicity Facts:
- Incidence of serious adverse events: 0.04% in postmarketing surveillance 1
- Most hepatotoxicity cases occurred in patients with pre-existing liver disease or serious underlying systemic conditions 2
- Symptomatic presentation is the rule: A 2017 systematic review found that all patients with terbinafine-induced severe liver injury were symptomatic—no asymptomatic cases were identified through laboratory screening alone 3
- Mean time to symptom onset: 30.2 days (range 5-84 days), with most cases occurring between 4-6 weeks 3
Clinical Presentation of Hepatotoxicity:
Symptoms in order of frequency 3:
- Jaundice (most common)
- Flu-like symptoms
- Dark urine
- Pruritus
- Right upper abdominal pain
- Nausea, anorexia, fatigue, vomiting
Monitoring Recommendations
Baseline Assessment (MANDATORY):
Before prescribing terbinafine, obtain:
Additional baseline monitoring is specifically recommended for:
- Patients with history of heavy alcohol consumption 1
- Patients with hepatitis 1
- Patients with hematological abnormalities 1
- Pediatric patients (as terbinafine is unlicensed for children) 1
During Treatment:
Routine periodic laboratory monitoring is NOT recommended based on the 2017 critically appraised topic that found no asymptomatic cases detected through screening and no meaningful time point for monitoring 3. The FDA label states "periodic monitoring of liver function tests is recommended" 2, but this conflicts with the clinical evidence showing all cases are symptomatic.
Instead, the evidence-based approach is:
- Patient education is paramount: Warn patients to immediately discontinue terbinafine and seek medical attention if they develop symptoms of liver injury 2
- Symptom-triggered evaluation: If symptoms develop, immediately check liver function tests 2
Contraindications:
Do NOT use terbinafine in patients with:
When to Discontinue:
Immediately stop terbinafine if:
- Biochemical or clinical evidence of liver injury develops 2
- Elevation of liver function tests occurs 2
- Patient develops symptoms suggestive of hepatotoxicity 2
Important Caveats
Common pitfall: Over-monitoring with routine laboratory tests. The evidence shows this does not detect hepatotoxicity before symptoms appear 3. Focus resources on thorough patient education about warning symptoms instead.
Reassuring data: Recent real-world studies show low rates of transaminase elevation (9.6% in one 2025 study) with no cases of actual hepatotoxicity, and all elevations were reversible after drug withdrawal 4. Another 2023 study found no patients discontinued treatment due to hepatotoxicity 5.
Prognosis: When recognized early and the drug is discontinued, the prognosis is often good with appropriate supportive treatment 6. Patients typically experience symptoms for a median of 16 days before seeking medical attention 3.